AcuCort Bilan de santé

Santé financière contrôle des critères 4/6

AcuCort possède un total de capitaux propres de SEK51.0M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK53.9M et de SEK2.9M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 11.73m
Fonds propres	SEK 51.01m
Total du passif	SEK 2.86m
Total des actifs	SEK 53.88m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ACUC ( SEK13.3M ) dépassent ses passifs à court terme ( SEK2.9M ).

Passif à long terme: ACUC n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: ACUC est sans dette.

Réduire la dette: ACUC n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ACUC dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ACUC dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 24 % chaque année

AcuCort Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

All Patients Completed AcuCort's Phase IV Study ZEQ001

New major risk - Market cap size

AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024

Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At Pharmacies

AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024

AcuCort AB (publ), Annual General Meeting, Jun 04, 2024

First quarter 2024 earnings released

AcuCort AB (publ) Provides Update on Phase IV Study ZEQ001

AcuCort AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Chief Executive Officer exercised options to buy kr161k worth of stock.

New minor risk - Share price stability

AcuCort AB (publ) Announces Update on FDA Application Ahead of Launch in the USA

Full year 2023 earnings released: kr0.44 loss per share (vs kr0.47 loss in FY 2022)

Insufficient new directors

AcuCort AB (publ) Announces First Patient Using Zeqmelit in Study Ahead of Market Launch

AcuCort AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

New major risk - Shareholder dilution

Third quarter 2023 earnings released

AcuCort AB (publ) has completed a Composite Units Offering.

AcuCort AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released

AcuCort AB (publ) to Report Q2, 2023 Results on Aug 31, 2023

AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023

AcuCort Receives Ethics Approval for Study with Zeqmelit®

Fda Requests Additional Information Prior to Acucort's Registration Application in the United States

AcuCort AB (publ), Annual General Meeting, May 04, 2023

AcuCort AB (publ) to Report Fiscal Year 2022 Final Results on Feb 24, 2023

AcuCort Submitted the Price and Subsidy Application to TLV Regarding Zeqmelit®

Acucort Receives Market Approval from the Finnish Medicines Agency for the Drug Zeqmelit

Acucort AB (Publ) Receives Granted Patent in Canada for the Company's Drug Zeqmelit™

AcuCort AB (publ) to Report Q3, 2022 Results on Nov 11, 2022

AcuCort Reports Positive Results from the Company's Questionnaire Study About Allergy Treatments

AcuCort AB (publ) Receives Marketing Authorization for the Drug Zeqmelit by the Norwegian Medicines Agency

AcuCort AB (publ) Receives Marketing Authorization for the Drug Zeqmelit by the Danish Medicines Agency

Second quarter 2022 earnings released

AcuCort AB (publ) to Report Q2, 2022 Results on Aug 12, 2022

No independent directors

Full year 2021 earnings released: kr0.58 loss per share (vs kr0.40 loss in FY 2020)

AcuCort AB (publ) to Report Q1, 2022 Results on Apr 28, 2022

AcuCort AB (publ) to Report Q1, 2022 Results on Apr 28, 2022

AcuCort AB (publ) is Exempted from the Application Fee by the U.S. Food and Drug Administration

New 90-day low: kr4.61

New 90-day low: kr5.12

New 90-day low: kr5.16

AcuCort AB (publ) Announces That the China National Intellectual Property Administration Has Granted the Company's Patent Application for Its Drug ISICORT®

AcuCort AB (publ) to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - kr7.16

AcuCort AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr5.24

New 90-day high - kr4.43

AcuCort AB (publ) Appoints Jonas Jönmark as New CEO, Effective August 9, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines